ERDAFITINIB + Carboplatin + CETRELIMAB + CISPLATIN

1 treatment and condition followed through the public trial records. Not medical advice. How a status is set

Treatments and conditions

ERDAFITINIB + Carboplatin + CETRELIMAB + CISPLATIN
Treatment and conditionWhere it standsTrials
ERDAFITINIB + Carboplatin + CETRELIMAB + CISPLATIN for carcinoma, transitional cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1